(S)-2-(Boc-Amino)non-8-Enoic Acid CAS 300831-21-4 Purity >98,0% (GC) ee >99,0% Paritaprevir Intermediate Factory

Katerangan pondok:

Ngaran: (S)-2-(Boc-Amino)non-8-Enoic Acid

CAS: 300831-21-4

Kamurnian: > 98,0% (GC)

ee: >99,0%

Penampilan: Cairan coklat

Panganteur Paritaprevir (CAS: 1216941-48-8)

E-Mail: alvin@ruifuchem.com

Kirim surélék ka kami

Rincian produk

Produk patali

Tag produk

Katerangan:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (S)-2-(Boc-Amino)non-8-Enoic Acid (CAS: 300831-21-4) with high quality, commercial production. Ruifu Chemical offers a wide range of chiral compounds. We can provide Certificate of Analysis (COA), worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com

Sipat Kimia:

Ngaran Kimia	(S)-2-(Boc-Amino)non-8-Enoic Acid
sinonim	(S)-2-(tert-Butoxycarbonylamino)non-8-Enoic Acid;(S)-2-(Boc-Amino)-8-Asam Nonenoat;(2S) -2- [(2-Methylpropan-2-yl)oxycarbonylamino]non-8-Enoic Acid;(2S)-2-{[(tert-Butoxy)karbonil]amino}non-8-Enoic Acid
Nomer CAS	300831-21-4
Nomer CAT	RF-CC347
Status saham	Aya sasayogian
Formula Molekul	C14H25NO4
Beurat Molekul	271.35
Kapadetan	1,035±0,06 g/cm3
merek	Kimia Ruifu

spésifikasi:

Barang	spésifikasi
Penampilan	Cairan Coklat
Purity / Métode Analisis	> 98,0% (GC)
ee	>99.0%
Standar tés	Standar Perusahaan
Pamakéan	Panganteur Paritaprevir (CAS: 1216941-48-8)

Paket & Panyimpenan:

Bungkusan: Botol Fluorinated, 25kg / Drum, atawa nurutkeun sarat customer urang

Kaayaan Panyimpenan:Simpen dina wadah anu disegel dina tempat anu tiis sareng garing;Ngajaga tina cahaya sareng Uap

Kaunggulan:

FAQ:

Aplikasi:

(S) -2-(Boc-Amino)non-8-Enoic Acid (CAS: 300831-21-4) tiasa dianggo salaku perantara dina sintésis Paritaprevir (CAS: 1216941-48-8) sareng analog anu aya hubunganana.Paritaprevir mangrupikeun inhibitor protease NS3 / 4A generasi kadua, mangrupikeun komponén terapi kombinasi virus hépatitis C tanpa interferon, anu dikembangkeun ku Enanta Pharmaceuticals sareng AbbVie.Tablet dosis tetep tina Paritaprevir, Ombitasvir sareng Ritonavir dicandak digabungkeun sareng Dasabuvir disatujuan pikeun pengobatan genotip 1 HCV kronis di AS sareng EU di 2014, sareng disatujuan pikeun pengobatan genotype 4 inféksi HCV kronis tanpa sirosis ku AS. FDA dina 2015.